Non-Small Cell Lung Cancer (ASCO) Basic Listing

Updates in Non-Small Cell Lung Cancer

From the ASCO Annual Meeting

Conference Coverage

Concurrent Osimertinib Improved PFS Among Patients With Unresectable, Stage 3 EGFR-Mutated Non-Small Cell Lung Cancer

06/02/2024

Suresh Ramalingam, MD

Suresh Ramalingam, MD, discussed results from the phase 3 LAURA study which demonstrated that administration of osimertinib following definitive chemoradiation improved PFS among patients with unresectable, stage 3, EGFR-mutated NSCLC.

Suresh Ramalingam, MD, discussed...

06/02/2024

Oncology

Paul Paik, MD, Memorial Sloan Kettering Cancer Center

Videos

Tepotinib Demonstrates Durable Clinical Activity Among Patients With MET Exon 14 Skipping Non-Small Cell Lung Cancer

07/17/2023

Featuring Paul Paik, MD

At the 2023 ASCO Annual Meeting, Paul Paik shared the long-term outcomes of tepotinib for patients with MET exon 14 skipping non-small cell lung cancer.

At the 2023 ASCO Annual Meeting,...

07/17/2023

Oncology

Ticiana Leal, MD, Winship Cancer Institute

Videos

Tumor Treating Fields Plus Standard of Care Improved Overall Survival Among Patients With Metastatic Non-Small Cell Lung Cancer

07/17/2023

Featuring Ticiana Leal, MD

At the 2023 ASCO Annual Meeting, Ticiana Leal, MD, discussed the results of the phase 3 LUNAR study, which found that the addition of tumor treating fields to standard of care improved overall survival among patients with metastatic non-small...

At the 2023 ASCO Annual Meeting,...

07/17/2023

Oncology

Videos

Adjuvant Osimertinib Improved Overall Survival for Patients With EGFR-Mutant NSCLC

06/19/2023

At the 2023 ASCO Annual Meeting, Roy Herbst, MD, PhD, shared results from the overall survival analysis of the phase 3 ADAURA trial, evaluating adjuvant osimertinib for patients with resected EGFR-mutated non-small cell lung cancer.

At the 2023 ASCO Annual Meeting,...

06/19/2023

Oncology

Sunvozertinib Demonstrates Superior Antitumor Efficacy Over Current Available Therapy for NSCLC With EGFR Exon20 Insertion Mutations

06/19/2023

Stephanie Holland

Results from the phase 2 WU-KONG6 study demonstrate superior antitumor efficacy with sunvozertinib in pretreated patients with NSCLC and EGFR exon20 insertion mutations when compared to current available therapies.

Results from the phase 2...

06/19/2023

Oncology

Conference Coverage

Datopotamab Deruxtecan Demonstrates Safety, Activity Among Patients With Non-Small Cell Lung Cancer

06/09/2023

Stephanie Holland

Findings from the phase 1b TROPION-Lung02 study presented at the 2023 ASCO Annual Meeting, demonstrate tolerable safety and notable first-line activity with datopotamab deruxtecan plus pembrolizumab among patients with NSCLC.

Findings from the phase 1b...

06/09/2023

Oncology

Conference Coverage

BLU-495 Demonstrates Safety and Activity in Advanced EGFR-Mutant NSCLC

06/09/2023

Amber Denham

According to phase 1/2 data presented at the 2023 ASCO Annual Meeting, BLU-945, as a monotherapy and in combination with osimertinib, was generally well tolerated and showed strong on-target EGFR ctDNA reduction.

According to phase 1/2 data...

06/09/2023

Oncology

Videos

PALOMA Study Identifies Recommended Phase 2 Dose of Subcutaneous Amivantamab for Advanced Solid Malignancies

06/04/2023

Anna Minchom, MBBCh, MRCP, MD(Res), discusses updated safety results from the PALOMA trial and the identified recommended phase 2 dose for subcutaneous biweekly administration of amivantamab for patients with advanced solid malignancies.

Anna Minchom, MBBCh, MRCP,...

06/04/2023

Oncology

Recent News

Conference Coverage

Lorlatinib Provides Longest Progression Free Survival Ever Seen for Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer

06/02/2024

Allison Casey

According to updated data presented at the 2024 ASCO Annual Meeting, lorlatinib has provided the longest progression-free survival ever reported among patients with advanced ALK-positive non-small cell lung cancer.

According to updated data...

06/02/2024

Oncology

Conference Coverage

Vibostolimab Coformulated With Pembrolizumab Showed Promising Activity Among Patients With dMMR Endometrial Cancer

06/02/2024

Allison Casey

The phase 2 KEYVIBE-005 study found vibostolimab coformulated with pembrolizumab had durable antitumor activity and manageable safety among patients with advanced mismatch repair deficient (dMMR) endometrial cancer.

The phase 2 KEYVIBE-005 study...

06/02/2024

Oncology

News

Cytopenias/Proliferation Define Outcomes for Patients With Primary MF and MF from Essential Thrombocythemia or PV

05/31/2024

Amber Denham

Cytopenias and/or proliferation, over JAK2 allele burden, correlate with outcomes of patients with primary myelofibrosis and with myelofibrosis from essential thrombocythemia or polycythemia vera, according to data presented at the 2024...

Cytopenias and/or proliferation,...

05/31/2024

Oncology

Conference Coverage

Inavolisib Plus Palbociclib and Fulvestrant Showed Clinical Benefit Post-Progression Among Patients With PIK3A-Mutated, HR-Positive, HER2-Negative Breast Cancer

05/31/2024

Stephanie Holland

According to updated results from the INAVO120 trial, inavolisib plus palbociclib and fulvestrant sustained clinical benefit beyond disease progression among patients with PIK3A-mutated, HR-positive, HER2-negative, locally advanced or...

According to updated results...

05/31/2024

Oncology

News

Oral Decitabine and Cedazuridine Plus Venetoclax Shows Efficacy, Safety for Older or Unfit Patients With AML

05/31/2024

By Gina Tomaine

Decitabine and cedazuridine plus venetoclax demonstrated efficacy as a fully oral regimen and was found to be safe for older or unfit patients with acute myeloid leukemia, according to a phase 2 study.

Decitabine and cedazuridine plus...

05/31/2024

Oncology

News

First-Line Sintilimab With Pegaspargase, Gemcitabine, and Oxaliplatin for Patients With Advanced Extranodal Natural Killer/T-Cell Lymphoma

05/29/2024

Amber Denham

According to results from a phase 2 trial, the combination of sintilimab with pegaspargase, gemcitabine, and oxaliplatin exhibits efficacy and safety as a frontline regimen among patients with advanced extranodal natural killer/T-cell...

According to results from a...

05/29/2024

Oncology

News

Abemaciclib Plus Nonsteroidal Aromatase Inhibitor Improved Survival Outcomes Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

05/23/2024

Stephanie Holland

According to final overall survival results from the MONARCH 3 study, abemaciclib plus a nonsteroidal aromatase inhibitor improved overall survival and prolonged progression-free survival among patients with HR-positive, HER2-negative...

According to final overall...

05/23/2024

Oncology

News

Addition of Relatlimab to Nivolumab and Chemotherapy Did Not Improve Response Among Patients With Unresectable, Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer

05/23/2024

Stephanie Holland

According to results from the phase 2 RELATIVITY-060 study, the addition of relatlimab to nivolumab and chemotherapy did not improve objective response among patients with unresectable, locally advanced or metastatic gastric or...

According to results from the...

05/23/2024

Oncology

News

Pembrolizumab Monotherapy Shows Promise Among Patients With BCG-Unresponsive, High-Risk NMIBC With Papillary Tumors, Without Carcinoma in Situ

05/22/2024

Stephanie Holland

According to results from cohort B of the phase 2 KEYNOTE-057 trial, pembrolizumab monotherapy demonstrated promising activity with manageable toxicity among patients with Bacillus Calmette-Guerin–unresponsive, high-risk non-muscle invasive...

According to results from cohort...

05/22/2024

Oncology

News

First-Line Brentuximab Vedotin Combined With Dacarbazine or Nivolumab for Older Patients With Classical Hodgkin Lymphoma

05/20/2024

Amber Denham

According to a phase 2 study, brentuximab vedotin combined with dacarbazine or nivolumab demonstrate safety and durable efficacy as a promising treatment alternative for older patients with classical HL unfit for initial conventional...

According to a phase 2 study,...

05/20/2024

Oncology